# Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

Source: https://onco.cc/trials/nct05866432/  
OnCo record `nct05866432` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by Medical University of Vienna, now recruiting.

## Summary

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases is a phase 2, interventional study registered as NCT05866432 by Medical University of Vienna, with a registry enrolment figure of 20 participants, started 2023-07-01 and due to reach its primary completion in 2026-05-23. Interventions recorded: Datopotamab deruxtecan. Conditions listed: Breast Cancer Stage IV. Triple-negative eligibility wording from the registry: "* Triple-negative disease as defined by immunohistochemistry (IHC) and/or c-erb-B2 gene amplification status". Sites: Austria. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TUXEDO-2
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05866432
- Phase: 2
- Setting: Phase II Study of Datopotamab-Deruxtecan (Dato-DXd; DS-1026a) in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
- Sponsor: Medical University of Vienna
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT05866432: https://clinicaltrials.gov/study/NCT05866432

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/)

---
JSON: https://onco.cc/api/v1/entities/nct05866432.json